Somatostatin receptor-positive breast lesions on 68Ga-DOTATATE PET/CT

被引:2
作者
Simsek, Duygu Has [1 ]
Isik, Emine Goknur [1 ]
Engin, Muge Nur [1 ]
Kuyumcu, Serkan [1 ]
Mudun, Ayse [1 ]
Sanli, Yasemin [1 ]
机构
[1] Istanbul Univ, Istanbul Fac Med, Dept Nucl Med, TR-34093 Istanbul, Turkey
关键词
Somatostatin receptor; Breast lesions; Ga-68-DOTATATE PET; CT; CANCER; SCINTIGRAPHY;
D O I
10.1007/s12149-020-01570-8
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective This study sets out to evaluate patients with increased uptake in breast lesions on Ga-68-DOTATATE PET/CT (DOTA PET) and determine the clinical significance of somatostatin receptor (SSTR) positive breast lesions. Methods We retrospectively evaluated all patients with increased SSTR uptake in breast lesions on DOTA PET. Patients with physiological (e.g., lactation) or normal variant breast uptake (e.g., mild diffuse glandular uptake) were excluded. The maximum standard uptake value (SUVmax) was calculated using a manually drawn region of interest in the most intense uptake of breast lesions. All lesions were correlated with breast imaging, including mammography and ultrasonography. Histopathological correlation was performed if the lesion was suspicious for malignancy. Lesions were followed up radiologically (1-8 years). Results Out of 1573 retrospectively analyzed DOTA PET scans, the incidence of SSTR + breast lesions was measured as 1.1% (n = 18); however, 4 of 18 patients were excluded due to the lack of final diagnosis of lesions. The median age was 35 (range 14-58 years), and all patients were female. The median SUVmax of SSTR + breast lesions was 5.2 (range 1.5-12.6) for a total of 14 patients. Twelve patients had a single SSTR + breast lesion, while 2 patients had multiple SSTR + lesions on bilateral breasts. In 6 patients, single SSTR + lesions were considered as fibroadenoma; in 2 patients, multiple SSTR + lesions were considered as metastases of NET, based on correlative breast imaging. In 6 patients, histopathological confirmation was needed for the final diagnosis. Histopathologic findings confirmed fibroadenoma in 4 patients by biopsy, in 1 patient with surgical removal of the lesion. The last patient who had a history of IDC was diagnosed with a recurrence of IDC with biopsy. The median SUVmax was 5.1 (range 1.5-9.4) for malignant breast lesions and 5.4 (range 2.2-12.6) for benign breast lesions. Conclusion SSTR + breast lesions on DOTA PET are rarely seen in clinical practice. Uptakes of breast lesions in our cases were variable and not useful for differential diagnosis of lesions. It seems that SSTR + breast lesions should be evaluated with clinical and radiological characteristics, and correlative breast imaging and/or histopathological verification should be performed for suspicious lesions to avoid misdiagnosis.
引用
收藏
页码:270 / 277
页数:8
相关论文
共 50 条
  • [31] 68Ga-DOTATATE PET/CT in the evaluation of patients with neuroendocrine metastatic carcinoma of unknown origin
    Alonso, Omar
    Rodriguez-Taroco, Monica
    Savio, Eduardo
    Bentancourt, Cecilia
    Gambini, Juan P.
    Engler, Henry
    ANNALS OF NUCLEAR MEDICINE, 2014, 28 (07) : 638 - 645
  • [32] Incidental Finding of Cerebellar Medulloblastoma on 68Ga-DOTATATE PET/CT in a Patient With Appendiceal Carcinoid
    Chan, Mico
    Hsiao, Edward
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (11) : 886 - +
  • [33] Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours
    Levent Kabasakal
    Emre Demirci
    Meltem Ocak
    Clemens Decristoforo
    Ahmet Araman
    Yıldız Ozsoy
    Ilhami Uslu
    Bedii Kanmaz
    European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39 : 1271 - 1277
  • [34] Case report: Uncommon multiple metastases from occult breast cancer revealed by 68Ga-DOTATATE PET/CT
    Hu, Tianyuan
    Zhang, Rongqin
    Zhang, Bing
    He, Shanzhen
    Liu, Lian
    Zou, Yan
    Huang, Junhao
    Wang, Bing
    Hu, Ping
    Zhang, Zhanwen
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [35] Phosphaturic mesenchymal tumor demonstrated by 68Ga-DOTATATE PET/CT in a patient: a case report
    Abadi, Younes
    Mileva, Magdalena
    Leger, Marc-Andre
    Sidiras, Paschalis
    Artigas, Carlos
    Flamen, Patrick
    Karfis, Ioannis
    EJNMMI REPORTS, 2024, 8 (01)
  • [36] How often do we see incidental 68Ga-DOTATATE thyroid uptake in PET/CT in patients with neuroendocrine tumours?
    Kunikowska, Jolanta
    Matyskiel, Renata
    Zemczak, Anna
    Strzelczyk, Janusz
    Pawlak, Dariusz
    Kos-Kudla, Beata
    Krolicki, Leszek
    ENDOKRYNOLOGIA POLSKA, 2015, 66 (03) : 231 - 236
  • [37] Neurofibromatosis Type 2 Multiple Meningiomatosis and Vestibular Schwannomas on 68Ga-DOTATATE PET/CT
    Filizoglu, Nuh
    Ozguven, Salih
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (11) : E710 - E712
  • [38] Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors
    Toriihara, Akira
    Baratto, Lucia
    Nobashi, Tomomi
    Park, Sonya
    Hatami, Negin
    Davidzon, Guido
    Kunz, Pamela L.
    Iagaru, Andrei
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (11) : 2244 - 2251
  • [39] 68Ga-DOTATATE PET/CT: The Optimum Standardized Uptake Value (SUV) Internal Reference
    Ragab, Ahmed
    Wu, Jianrong
    Ding, Xue
    Clark, Aurela
    Mischen, Blaine
    Chauhan, Aman
    Oates, M. Elizabeth
    Anthony, Lowell
    El Khouli, Riham
    ACADEMIC RADIOLOGY, 2022, 29 (01) : 95 - 106
  • [40] Recurrent/Residual Intracranial Phosphaturic Mesenchymal Tumor Revealed on 68Ga-DOTATATE PET/CT
    Ding, Jie
    Wang, Ling
    Zhang, Shu
    Li, Fang
    Huo, Li
    CLINICAL NUCLEAR MEDICINE, 2018, 43 (09) : 674 - 675